Navigation Links
Hotspur Technologies Continues to Bring Innovations to Peripheral Vascular Market
Date:1/10/2011

MOUNTAIN VIEW, Calif., Jan. 10, 2011 /PRNewswire/ -- Hotspur Technologies, Inc. announced today that Dr. Bruce Lin, M.D., and Dr. Stephen Liu, M.D., Interventional Radiologists at Lifelink Interventional Center in Modesto, California, performed the first commercial deployment of the company's GPSCath™ Balloon Dilatation Catheter.  This new device enables, for the first time, multiple vascular procedures to be performed with one catheter, potentially reducing procedure time and expense for both patients and medical professionals.  

The GPSCath™ is a two-in-one device that allows physicians to perform high-pressure angioplasty and inject physician-specified fluids such as contrast while maintaining guidewire position.  

"The Hotspur GPSCath™ balloon is a superior alternative to a non-compliant ultra-high-pressure legacy devices currently in use," said Dr. Lin. "This is because the flexible nature of the Hotspur device allows tactile and visual feedback on the stenotic lesion, while still providing the performance of a ultra-high-pressure angioplasty balloon.  In addition, the value added feature enables operators to conveniently maintain guidewire position while delivering therapeutic drugs and evaluating results of interventions. This is especially attractive when treating difficult or occlusive lesions.  Hotspur is setting a higher bar for peripheral and dialysis access angioplasty performance."

During the first procedure, Dr. Liu successfully restored blood flow through the patient's dialysis access graft by inflating a 7mm GPSCath™ balloon to 20ATM to open a blockage within the graft.  After performing the angioplasty, without removing the balloon, Dr. Liu then opened the proprietary valve on the distal end of the GPSCath™ balloon catheter and successfully injected contrast to visualize the angioplasty result. Dr. Liu followed with a second procedure performing both functions utilizing a 6mm GPSCath™ balloon. In the past for these types of treatments, physicians typically had to perform multiple catheter exchanges to open the vessels and visualize results, which can be time-consuming and expensive due to the use of multiple catheters. Hotspur's products aim to use one catheter for the entire procedure.

"We are committed to enabling medical professionals to perform peripheral access procedures with devices that both simplify and improve the doctors' and patients' experiences," said Gwen Watanabe, president and CEO of Hotspur.  "Our key goal is to bring innovation to markets that have had less focus because they are so fragmented."  Watanabe indicated that, based on recently released data, there are almost 20 million patients with peripheral vascular disease that could benefit from this multi-purpose approach to catheter design for the peripheral access market.

The GPSCath is the one of three Hotspur devices that have received 510(k) clearance from the U.S. Food and Drug Administration.  These devices are focused on solving some of the key challenges associated with restoring blood flow to blocked or low flow dialysis access grafts and fistulaes and peripheral vessels. In addition to the GPSCath™, the IQCath™ Balloon Dilatation Catheter is a specialty three-in-one device that allows the physician to perform angioplasty, embolectomy, and fluid injection with the same catheter while maintaining guidewire position; and the Keeper™ Embolectomy Catheter is a specialty two-in-one device that integrates an embolectomy balloon with the ability to inject physician-specified fluids while maintaining guidewire position.

These products are commercially available in the United States. The foundation of Hotspur's commercial devices is a groundbreaking technology known as the VisioValve™ injection system. This innovation utilizes a proprietary valve system that allows a physician to perform angioplasty or clot removal and perform an injection of physician-specified fluids without having to remove the guidewire or exchange devices. Hotspur expects to develop a variety of other treatment devices based on this technology.

About Hotspur TechnologiesFounded in 2008 and located in Mountain View, California, Hotspur Technologies (www.hotspur-inc.com) is a leading developer of catheter-based technologies aimed at restoring blood flow for patients with obstructed vessels. The company's products are based on a unique technology that opens blood vessels more efficiently and less invasively. The firm's VisioValve technology serves as a launching point to improve patient outcome and physician efficiency. Hotspur is privately held.  Its investors include ONSET Ventures, Finistere Ventures, BioStar Ventures, Saratoga Ventures, Incept, G-Level, and Versant Ventures.For more press information contact:
Abigail Johnson
Roeder-Johnson Corporation
(650) 802-1850
http://email.roeder-johnson.com

For more customer information contact:
Hotspur Technologies
Mountain View, CA
(650) 969-3150
info@hotspur-inc.com
'/>"/>

SOURCE Hotspur Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hotspur Technologys Novel 3-in-1 Angioplasty Balloon Successfully Achieves First Commercial Deployment
2. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
3. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
4. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
5. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
6. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
7. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
8. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
9. Senesco Technologies Initiates Preclinical Studies for Cancer Target
10. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
11. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... N.Y. , Feb. 5, 2016  Henry Schein, ... health care products and services to office-based dental, animal ... entered into an agreement to acquire a majority ownership ... supplies and equipment in Brazil . ... Headquartered in Blumenau, Brazil, Dental Cremer is the dental distribution ...
(Date:2/4/2016)... For hospitals considering enrollment in the Federal ... the program, the Health Resources and Services Administration,s (HRSA) ... Mega-Guidance , could have significant impact on plans and ... 2016. Essential Insights , Daniel Neal, ... the Mega-Guidance,s key proposed changes, including a new requirement ...
(Date:2/4/2016)... 4, 2016   Bernstein Liebhard LLP today announced ... United States District Court for the District of ... consisting of all persons or entities who purchased common shares ... INSY ) from March 3, 2015 through January 25, 2016 ... its officers with violations of the Securities Exchange Act of ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... US Sports Camps , official operators of Nike ... high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in the picturesque New ... ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are thrilled to be ...
(Date:2/5/2016)... ... , ... Give To Cure today announced that it is working ... To Cure’s campaign that is crowdfunding clinical trials to help find cures faster for ... a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... in need. The event is scheduled to take place on February 27, 2016 from ... dental care to community members in need. Each patient will be given the opportunity ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of ... A hallmark feature of patients with eating disorders is significant self-criticism, and consequently these ... and obsessions are regarded as maladaptive means for coping with this unease, but also ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Calls Blacklist has ... completely new user interface design and the developer has fixed known bugs within the ... want to on their phone while not consuming any of their device’s battery power ...
Breaking Medicine News(10 mins):